Neurourology and Urodynamics, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 7, 2024

ABSTRACT Introduction Detrusor muscle weakness is commonly noted on urodynamics in patients with refractory voiding difficulty. No approved therapies have been proven to augment the strength of a detrusor contraction. Methods This subject was discussed by think‐tank at International Consultation Incontinence‐ Research Society (ICI‐RS) meeting held Bristol, June 2024. The discussions are being published two parts. first part discusses molecular and stem cell targeting urinary bladder neural axis. Results Senescence urothelium extracellular ATP acting through P2X3 receptors might be important underactivity. Several molecules such as parasympathomimetics, acotiamide, ASP8302, neurokinin‐2 agonists explored but none has shown unequivocal clinical benefit. Different therapy approaches used, chiefly neurogenic dysfunction, some studies showing Molecular targets for axis included TRPV‐4, Bombesin, serotoninergic TAC‐302 which induces neurite growth. Conclusions options currently pursued search an elusive or option enhancing power muscle. These encompass wide range that target each aspect contraction mechanism including urethra, myocyte, pathways. While these utility, appear promising. Lessons from other fields medicine prove instructive. Clinical Trial Registration Not necessary. trial.

Language: Английский